Generics in Belgium

Generics in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2010-14, and forecast to 2019). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Belgian generics market is expected to generate total revenues of $596.6m in 2014, representing a compound annual growth rate (CAGR) of 4.4% between 2010 and 2014.

Market consumption volume is forecast to increase with a CAGR of 4.5% between 2010 and 2014, to reach a total of 27.9% of total pharma volume in 2014.

The performance of the market is forecast to decelerate, with an anticipated CAGR of 3% for the five-year period 2014 – 2019, which is expected to drive the market to a value of $690.7m by the end of 2019.

Scope

Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Belgium

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Belgium

Leading company profiles reveal details of key generics market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Belgium generics market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Belgium economy

Reasons to buy

What was the size of the Belgium generics market by value in 2014?

What will be the size of the Belgium generics market in 2019?

What factors are affecting the strength of competition in the Belgium generics market?

How has the market performed over the last five years?

Companies mentioned

Mylan Inc., Sandoz International GmbH, Sanofi SA and Teva Pharmaceutical Industries Limited

Table of Contents

TABLE OF CONTENTS

Executive Summary 2

Market value 2

Market value forecast 2

Market volume 2

Market volume forecast 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 8

Market value 8

Market volume 9

Market Segmentation 10

Geography segmentation 10

Market Outlook 11

Market value forecast 11

Market volume forecast 12

Five Forces Analysis 13

Summary 13

Buyer power 14

Supplier power 15

New entrants 16

Threat of substitutes 17

Degree of rivalry 18

Leading Companies 19

Mylan Inc. 19

Sandoz International GmbH 22

Sanofi SA 23

Teva Pharmaceutical Industries Limited 26

Macroeconomic Indicators 29

Country Data 29

Appendix 31

Methodology 31

Industry associations 32

Related MarketLine research 32

LIST OF TABLES

Table 1: Belgium generics market value: $ million, 201014(e) 8

Table 2: Belgium generics market volume: % of total pharma volume, 201014(e) 9

Table 3: Belgium generics market geography segmentation: $ million, 2014(e) 10

Table 4: Belgium generics market value forecast: $ million, 201419 11

Table 5: Belgium generics market volume forecast: % of total pharma volume, 201419 12

Table 6: Mylan Inc.: key facts 19

Table 7: Mylan Inc.: key financials ($) 20

Table 8: Mylan Inc.: key financial ratios 20

Table 9: Sandoz International GmbH: key facts 22

Table 10: Sanofi SA: key facts 23

Table 11: Sanofi SA: key financials ($) 24

Table 12: Sanofi SA: key financials (€) 24

Table 13: Sanofi SA: key financial ratios 24

Table 14: Teva Pharmaceutical Industries Limited: key facts 26

Table 15: Teva Pharmaceutical Industries Limited: key financials ($) 27

Table 16: Teva Pharmaceutical Industries Limited: key financial ratios 27

Table 17: Belgium size of population (million), 201014 29

Table 18: Belgium gdp (constant 2005 prices, $ billion), 201014 29

Table 19: Belgium gdp (current prices, $ billion), 201014 29

Table 20: Belgium inflation, 201014 30

Table 21: Belgium consumer price index (absolute), 201014 30

Table 22: Belgium exchange rate, 201014 30

LIST OF FIGURES

Figure 1: Belgium generics market value: $ million, 201014(e) 8

Figure 2: Belgium generics market volume: % of total pharma volume, 201014(e) 9

Figure 3: Belgium generics market geography segmentation: % share, by value, 2014(e) 10

Figure 4: Belgium generics market value forecast: $ million, 201419 11

Figure 5: Belgium generics market volume forecast: % of total pharma volume, 201419 12

Figure 6: Forces driving competition in the generics market in Belgium, 2014 13

Figure 7: Drivers of buyer power in the generics market in Belgium, 2014 14

Figure 8: Drivers of supplier power in the generics market in Belgium, 2014 15

Figure 9: Factors influencing the likelihood of new entrants in the generics market in Belgium, 2014 16

Figure 10: Factors influencing the threat of substitutes in the generics market in Belgium, 2014 17

Figure 11: Drivers of degree of rivalry in the generics market in Belgium, 2014 18

Figure 12: Mylan Inc.: revenues & profitability 20

Figure 13: Mylan Inc.: assets & liabilities 21

Figure 14: Sanofi SA: revenues & profitability 25

Figure 15: Sanofi SA: assets & liabilities 25

Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability 27

Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities 28

List of Tables

NA

List of Figures

NA

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports